Navigation Links
eResearchTechnology Reports First Quarter 2008 Results
Date:5/5/2008

13,555

Total current liabilities 32,962 26,203

Capital lease obligations, excluding

current portion 48 -

Other liabilities 1,174 1,167

Total liabilities 34,184 27,370

Stockholders' equity:

Preferred stock-$10.00 par value,

500,000 shares authorized, none

issued and outstanding - -

Common stock-$.01 par value,

175,000,000 shares authorized,

58,870,291 and 58,918,095 shares

issued, respectively 589 589

Additional paid-in capital 87,957 88,734

Accumulated other comprehensive

income 1,679 1,676

Retained earnings 85,477 91,223

Treasury stock, 8,247,119 shares

at cost (62,190) (62,190)

Total stockholders' equity 113,512 120,032

Total liabilities and

stockholders' equity $147,696 $147,402

eResearchTechnology, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

Three Months Ended March 31,

2007 2008

Operating activities:

Net income $2,248 $5,746

Adjustments to reconcile net income to

net cash provided by operating activities:

Depreciation and amortization 3,215 4,344

Cost of sales of equipment
'/>"/>

SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008
2. eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008
3. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
4. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
5. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
6. eResearchTechnology to Present at the UBS Global Healthcare Services Conference 2008 on February 11th
7. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
8. MannKind Corporation Reports First Quarter Financial Results
9. Verenium Reports Financial Results for the First Quarter 2008
10. ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
11. United Therapeutics Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled ... 2pm EST (11am PST), “Natural Language Processing: Converting Raw ... technology can turn raw, heterogeneous data into actionable knowledge ... online webinar will last approximately one hour. , Synopsis: ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2
... NEW YORK, March 1, 2012 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0788386/Global-Biotechnology-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechno The global outlook series ... anecdotes, market briefs, and concise summaries of ...
... 2012  Receptos Inc. today announced that the company is scheduled ... Care Conference at noon EST on Wednesday, March 7, 2012, ... Hasnain, president and chief executive officer, will provide an overview ... programs. "This is an exciting time at ...
... Laboratories, Inc. (OTCBB: UGNE), a leader in the design, ... that the Company,s senior management team will host a ... 8, 2012 at 11 a.m. ET to discuss fourth ... Interested participants and investors may access the conference call ...
Cached Biology Technology:Global Biotechnology Industry 2Global Biotechnology Industry 3Global Biotechnology Industry 4Global Biotechnology Industry 5Global Biotechnology Industry 6Receptos to Present at the Cowen and Company 32nd Annual Health Care Conference 2Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012 2
(Date:4/23/2014)... "playwright" to their resumes in an effort to aid ... ethical issues as genomic science transitions to bedside healthcare, ... , Until now the plays of Karen H. ... and by, their peers and others in the genomics ... With Oxford University Press, publication of the book ...
(Date:4/23/2014)... is available in French and German . ... female? In humans and other mammals, the difference between sexes depends ... is present only in males, where the two sexual chromosomes are ... Y is ultimately responsible for all the morphological and physiological differences ... the case. A very long time ago, the X and Y ...
(Date:4/23/2014)... most in their mid-thirties and forties, face a ... within two decades. "Mutant" protein clusters, long blamed ... been the primary focus of therapies in development ... from Prof. Gerardo Lederkremer and Dr. Julia Leitman ... and Immunology, in collaboration with Prof. Ulrich Hartl ...
Breaking Biology News(10 mins):Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3Male or female? 2Male or female? 3On the defensive 2On the defensive 3
... nanometer and micron size scales could play a key ... improve the reliability, reduce the size and lower the ... by a team of scientists from the Georgia Tech ... the Naval Surface Warfare Center, the highly-uniform copper structures ...
... treat certain cancers and rheumatoid arthritis appears to greatly ... Medicine researchers report in the Journal of Clinical Investigation. ... continue to be observed long after the antibody is ... antibody, rituximab (anti-CD20), depletes B cells. Experimental evidence in ...
... or physical disabilities should not resort to a ... University. Lori Marino, senior lecturer in the Neuroscience ... Lilienfeld, professor in the Department of Psychology, to ... purveyors of what is known as dolphin-assisted therapy ...
Cached Biology News:Unique porous copper structure enables new generation of military micro-detonators 2Unique porous copper structure enables new generation of military micro-detonators 3Cancer and arthritis therapy may be promising treatment for diabetes 2Dolphin 'therapy' a dangerous fad, Emory researchers warn 2Dolphin 'therapy' a dangerous fad, Emory researchers warn 3
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
... designed for use with the ProQuest Two-Hybrid ... contains deletions in the endogenous GAL4 and ... systems. The strain also has leu2 and ... and prey vectors. MaV203 contains three GAL4 ...
Request Info...
Biology Products: